BXMPY (Beximco Pharmaceuticals) Inventories, Finished Goods: $25.53 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Beximco Pharmaceuticals Inventories, Finished Goods?

Beximco Pharmaceuticals BXMPY 93 Inventories, Finished Goods is $25.53 Mil as of Mar. 2026. GuruFocus rates BXMPY with a GF Score™ of 93/100. The stock has 5 warning signs investors should review.

Beximco Pharmaceuticals's quarterly finished goods increased from Sep. 2025 ($25.08 Mil) to Dec. 2025 ($26.33 Mil) but then declined from Dec. 2025 ($26.33 Mil) to Mar. 2026 ($25.53 Mil).

Beximco Pharmaceuticals's annual finished goods declined from Jun. 2023 ($28.87 Mil) to Jun. 2024 ($23.35 Mil) but then increased from Jun. 2024 ($23.35 Mil) to Jun. 2025 ($24.07 Mil).

Beximco Pharmaceuticals Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Beximco Pharmaceuticals's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beximco Pharmaceuticals Inventories, Finished Goods Chart

Beximco Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.19 20.84 28.87 23.35 24.07

Beximco Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 24.07 25.08 26.33 25.53

Beximco Pharmaceuticals Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of $25.53 Mil mean?
Beximco Pharmaceuticals (BXMPY) has a Inventories, Finished Goods of $25.53 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on Beximco Pharmaceuticals and its competitors.
Is Beximco Pharmaceuticals' Inventories, Finished Goods too high?
Beximco Pharmaceuticals' current Inventories, Finished Goods is $25.53 Mil. Overall, Beximco Pharmaceuticals has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' Inventories, Finished Goods compare to ZTS and UTHR?
Beximco Pharmaceuticals' Inventories, Finished Goods of $25.53 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Drug Manufacturers company?
A good Inventories, Finished Goods depends on the Drug Manufacturers industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Beximco Pharmaceuticals and its competitors. Beximco Pharmaceuticals's current Inventories, Finished Goods is $25.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Beximco Pharmaceuticals (BXMPY) has a current Inventories, Finished Goods of $25.53 Mil. The current Inventories, Finished Goods is $25.53 Mil. Beximco Pharmaceuticals' overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Beximco Pharmaceuticals (BXMPY), the current Inventories, Finished Goods is $25.53 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Beximco Pharmaceuticals Business Description

Address 19 Dhanmondi, Road No. 7, Dhaka, BGD, 1205
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.